CDX-110

February 5, 2012

Cancer Immunotherapy: A Roundtable Discussion

June 30, 2011 By MD Becker Partners 3 Comments

meeting desk

Beyond the approvals of both Provenge and Yervoy, there are a number of additional catalysts that could ignite further interest in the field of cancer immunotherapy.

Filed Under: Articles Tagged With: AGS-003, Allovectin-7, American Society of Clinical Oncology, Amgen, AMGN, AnGes, Argos Therapeutics, ASCO, AVAX Technologies, Bavarian Nordic, belagenpumatucel-L, BiovaxID, Biovest International, BLP25 liposome vaccine, BVTI, cancer immunotherapy, Cancer Research Institute, CDX-110, Celldex Therapeutics, CRI, GBM, GlaxoSmithKline, glioblastoma, GSK, Lucanix, MAGE-AS ASCI, melanoma, Merck KGA, MVA-MUC1-IL2, Novartis, Novarx, NSCLC, Oncothyreon, OncoVEX(GM-CSF), prostate cancer, PROSTVAC, rindopepimut, Stimuvax, TG4010, transgene, Vical, VICL

Ipilimumab Approval Highlights Immunotherapy Renaissance

March 25, 2011 By MD Becker Partners Leave a Comment

mab_slide

On March 25, 2011, Yervoy® [ipilimumab] by Bristol-Myers Squibb became the eleventh mAb approved by the FDA for the treatment of cancer.

Filed Under: Articles Tagged With: AGEN, Agenus, Allovectin-7, Amgen, AMGN, Antigenics, AVAX, AVAX Technologies, AVXT.PK, Bavarian Nordic, BIIB, Biogen Idec, BiovaxID, Biovest International, BioVex, BMY, Bristol-Myers Squibb, BVTI, CancerVax, Canvaxin, CDX-110, Celldex Therapeutics, CLDX, Corixa, Dendreon, DNDN, GlaxoSmithKline plc, GMK vaccine, GSK, ipilimumab, Lucanix, MAGE-A3 ASCI, Melacine, MVAX, Novarx, Oncophage, Oncothyreon, OncoVex, ONTY, Oxford BioMedica, PGNX, Progenics Pharmaceuticals, PROSTVAC, Rituxan, rituximab, Stimuvax, TG4010, transgene, Trovax, Vical, VICL, William Coley, Yervoy

Cancer Vaccine Therapies: Failures and Future Opportunities

April 7, 2010 By MD Becker Partners 3 Comments

FIGURE 1: FDA APPROVAL OF CANCER MABS FROM 1997-2010

(Note: the following text is an Executive Summary from our new 150-page report titled “Cancer Vaccine Therapies: Failures and Future Opportunities”) Since the early 1990s, cancer immunotherapy has provided hope to patients, physicians, and investors as a new treatment modality with limited side effects and superior efficacy. Cancer immunotherapy broadly includes passive immunization, active immunization, [...]

Filed Under: Articles Tagged With: active immunotherapy, AGEN, allogeneic, Allovectin-7, American Society for Clinical Oncology, Antigenics, Arzerra, ASCO, autologous, Bavarian Nordic, BIIB, Biogen Idec, Biologics License Application, biotechnology, BiovaxID, Biovest International, BMY, Bristol-Myers Squibb Company, BVTI, cancer vaccine, CD20, CDX-110, Celldex Therapeutics, CTLA-4, Dendreon, dendritic cells, DNDN, EGFRvIII, Genmab A/S, GlaxoSmithKline, GM-CSF, gp100, GSK, GVAX, immunotherapy, ipilimumab, life sciences, lung cancer, MAGE-3, MAGE-A3 ASCI, MD Becker Partners, melanoma, monoclonal antibodies, NCI, NHL, non-Hodgkin’s Lymphoma, NSCLC, ofatumumab, Oncophage, passive immunotherapy, PDUFA, PFE, Pfizer, prostate cancer, prostatic acid phosphatase, PROSTVAC, Provenge, RHHBY, Rituxan, rituximab, Roche Group, sipuleucel-T, TRICOM, vaccine, Vical, VICL